Related Experiment Video
Updated: Apr 21, 2026

Author Spotlight: Exploring Photodynamic Therapy with Curcumin in a Murine Model for Oral Candidiasis
Published on: October 27, 2023
A topical imiquimod-induced oral mucosal lichenoid reaction: a case report
Ronald S Brown1, Andre A Farquharson2
1Dr. Brown is a professor, Division of Oral Diagnosis and Radiology, Department of Comprehensive Dentistry, College of Dentistry, Howard University, Washington, and a clinical associate professor, Department of Otolaryngology-Head and Neck Surgery, Georgetown University Medical Center, Washington. Address correspondence to Dr. Brown at the Division of Oral Diagnosis and Radiology, Department of Comprehensive Dentistry, College of Dentistry, Howard University, 600 W St., NW, Washington, D.C. 20059, e-mail rbrown@howard.edu.
Background:
Imiquimod (IMI) is a topical immune response modifier used in the treatment of actinic keratosis and cheilitis. Actinic cheilitis is a potentially premalignant condition that requires therapeutic intervention. IMI therapy is noted for producing cutaneous and mucosal adverse effects. The authors report the case of an 88-year-old woman who was treated for actinic cheilitis of the upper lip with IMI and who consequently experienced an oral mucosal lichenoid reaction of the lower lip and right buccal mucosa.
Results:
The patient was treated successfully with high-dose steroid therapy, and the oral lesions resolved in 17 days.
Conclusions:
To our knowledge, this is the first case report regarding an IMI-induced oral mucosal lichenoid reaction. Clinicians should be aware of the potential of IMI to cause lichenoid reactions.
Practical Implications:
IMI is an efficacious therapeutic agent when used in the treatment of actinic cheilitis, but it is prone to cause oral mucosal side effects such as lichenoid reactions. Therefore, it is important for dentists to be knowledgeable concerning potential mucosal IMI side effects.
Related Concept Videos
Hypersensitivity Reactions: Cytolytic Reactions
Skin Cancer
Basal Cell Carcinoma (BCC): BCC is the most common type of skin cancer, accounting for about 80% of cases. It typically develops in...
Hypersensitivity Reactions: Immune-Complex Reactions